technetium-tc-99m-medronate and Liver-Diseases

This case report describes diffuse hepatic uptake of a diphosphonate bone scan agent (Technetium-99m-MDP) in a patient with amyloidosis associated with a plasma cell dyscrasia. Amyloid infiltration is one of the more rare, but well recognized, causes of hepatic uptake of bone scan tracer. Other causes are also discussed in this case report.

Topics: Aged; Amyloidosis; Bone and Bones; Female; Humans; Liver; Liver Diseases; Paraproteinemias; Radionuclide Imaging; Technetium Tc 99m Medronate

A patient with AA amyloidosis secondary to ankylosing spondylitis showed intense liver uptake of Tc-99m MDP on bone imaging. The biopsy showed hepatic amyloid deposition. A repeat bone scan with Tc-99m MDP 1 year later was negative, although the clinical signs and liver function tests of the patient had not changed. A mechanism might exist, other than the affinity of amyloid to calcium, which would explain the extraosseous uptake of pyrophosphates and diphosphonates in organs and soft tissues affected by systemic amyloidosis.

Topics: Amyloidosis; Diphosphates; Humans; Liver; Liver Diseases; Male; Middle Aged; Radiography; Radionuclide Imaging; Spondylitis, Ankylosing; Technetium; Technetium Tc 99m Medronate; Technetium Tc 99m Pyrophosphate

A child with diffuse accumulation of [99mTc]MDP in the liver on a bone scan, at the time of study the patient had a severe, but reversible, hepatic dysfunction on the basis of methotrexate toxicity. Visualization of the liver on skeletal scintigrams can be a consequence of high-dose methotrexate therapy, as there was no other explanation for this unusual finding.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Child; Female; Humans; Liver Diseases; Methotrexate; Radionuclide Imaging; Technetium Tc 99m Medronate

A case of diffuse hepatic uptake of Tc-99m MDP in an intravenous drug abuser with biopsy-proven hepatic amyloidosis is presented. The association of parenteral drug addiction and amyloidosis, as well as current concepts regarding hepatic uptake of bone seeking radiopharmaceuticals in amyloidosis and its potential clinical implications are discussed.

Topics: Adult; Amyloidosis; Bone and Bones; Humans; Injections, Intravenous; Liver; Liver Diseases; Male; Radionuclide Imaging; Substance-Related Disorders; Technetium Tc 99m Medronate

A prospective, comparative study was made of the efficacy of technetium-99m pyrophosphate (Tc PYP) and technetium-99m methylene diphosphonate (Tc MDP) in detecting soft-tissue amyloidosis. Tc PYP and Tc MDP scans were obtained within ten-day intervals in seven patients with histologically proven amyloidosis. Tc PYP was a better scanning agent for soft-tissue amyloidosis in all patients. Cardiac and hepatic involvement were proved by autopsy in one patient. Involvement of the heart was confirmed by echocardiography in five patients. The potential use of Tc PYP scanning as a screening test for soft-tissue amyloidosis is discussed.

Topics: Adult; Aged; Amyloidosis; Biopsy; Diphosphates; Diphosphonates; Echocardiography; Female; Heart Diseases; Humans; Liver Diseases; Male; Middle Aged; Prospective Studies; Radionuclide Imaging; Technetium; Technetium Tc 99m Medronate; Technetium Tc 99m Pyrophosphate